Cytokinetics, Incorporated (CYTK) Stock: A Biotechnology Stock That’s Falling


Cytokinetics, Incorporated (CYTK) is working its way for to the bottom in the market today. The stock, one that is focused on the biotech industry, is currently priced at $8.84 after tumbling -13.25% so far today. In terms of biotech companies, there are a number of factors that have the potential to cause movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines relating to CYTK:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 07:51AM The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Mar-20-19 04:51PM Here’s Why Cytokinetics Stock Jumped Today
08:30AM Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
08:30AM Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Mar-18-19 04:00PM Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19

However, any time investors are making an investing decision, prospective investors should look into much more than news, this is especially the case in the highly speculative biotech space. Here’s what’s happening in regard to Cytokinetics, Incorporated.

The Performance That We’ve Seen From CYTK

While a decline in a single session, like the move that we’re seeing from Cytokinetics, Incorporated may cause fear in some investors, a single session move alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is generally a good idea to look into trends further out than a single trading session. As it relates to CYTK, below are the movements that investors have seen:

  • Past 5 Sessions – Throughout the last five trading sessions, CYTK has produced a change in price in the amount of 17.55%.
  • Past Month – The performance from Cytokinetics, Incorporated over the past 30 days has been 20.44%.
  • Quarterly – In the last three months, the company has generated a return on investment that comes to 25.57%
  • Past 6 Months – In the last six months, investors have seen a change that equates to 4.00% from the company.
  • YTD – Since the open of this year CYTK has generated a return of 39.87%.
  • Full Year – Lastly, over the last full year, we have seen a change that works out to 2.79% out of CYTK. Over this period of time, the stock has traded at a high of -15.33% and a low price of 53.74%.

Key Ratios

Digging into various ratios associated with a stock generally gives prospective investors a view of just how dangerous and/or rewarding a pick might be. Below are some of the key ratios to think about when looking at CYTK.

Short Ratio – The short ratio is a tool that’s used to measure the level of short interest. As the ratio heads up, it shows that more investors are expecting that the price of the stock is headed for declines. In general, biotech stocks can come with a higher short ratio. However, we also tend to see a lot of short squeezes in the sector. Nonetheless, in regard to Cytokinetics, Incorporated, it’s short ratio comes to 4.71.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure whether or not a company can pay for its debts when they mature with only current assets or quick assets. Because many biotech several companies are reliant on the continuation of investor support, the quick and current ratios can look upsetting. Nonetheless, quite a few better companies in the biotech sector do have positive current and quick ratios. In terms of CYTK, the quick and current ratios work out to 10.60 and 10.60 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In this particular case, that ratio is 0.95.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotech industry, this is a very important ratio to think about. In this case, the cash to share value comes to 3.97.

Analyst Opinions With Regard To Cytokinetics, Incorporated

Although it’s rarely a good idea to unknowingly follow the opinions of analysts, it is a good idea to use their analysis when validating your own opinions when it comes to making investment decisions in the biotech space. Below are the most recent moves that we’ve seen from analysts with regard to CYTK.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-21-18 Initiated Cantor Fitzgerald Overweight
Sep-10-18 Resumed Morgan Stanley Equal-Weight $10
Nov-22-17 Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17 Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17 Reiterated H.C. Wainwright Buy $26 → $17

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CYTK, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors own 73.60% of the company. On the other hand, it’s worth noting that institutional ownership has moved in the amount of 2.89% over the last 3 months.
  • Insider Holdings – as it relates to insiders, members of the management team and others close to CYTK currently hold 0.50% of the company. Their ownership of the company has moved -8.62% over the last quarter.

Looking At Share Counts

Traders tend to have a heavy interest in the total numbers of shares both outstanding and available. With respect to Cytokinetics, Incorporated, there are currently 52.99M with a float of 50.86M. These data mean that of the total of 52.99M shares of CYTK that are out there today, 50.86M are available to trade hands by the public.

I also find it important to dig into the short percentage of the float. After all, when a high percentage of the float available for trading is sold short, the overall feeling among traders is that the company is going to take a dive. As far as CYTK, the percentage of the float that is sold short is 5.06%. Most investors would say that a concerning short percent of the float is anything over 40%. In my research, I’ve calculated that any short percent of the float over 26% is usually a a play that could prove to be very risky.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.72. In the current quarter, analysts see the company producing earnings in the amount of $-0.48. Over the last 5 years, CYTK has generated revenue in the amount of $0.60% with earnings coming in at -9.60%. On a quarter over quarter basis, earnings have seen movement of 33.10% and revenue has seen movement of 71.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I can learn by myself. Nonetheless, I was made by a human and human beings play an important part in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I learn much faster when I have the help of a teacher. If you would to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here